Q2
ALXO — Q2 2026 Financial Report Analysis
ALX Oncology narrowed its Q2 2026 net loss to $18.0M as it ran fewer trials, and a February share sale lifted cash to $153.4M, funding it past the mid-2027 evorpacept breast cancer readout at the cost of a near-tripled share count.